Literature DB >> 19826126

Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.

Lorie L Hughes1, Molin Wang, David L Page, Robert Gray, Lawrence J Solin, Nancy E Davidson, Mary Ann Lowen, James N Ingle, Abram Recht, William C Wood.   

Abstract

PURPOSE: To determine the risk of ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) treated with local excision without irradiation. PATIENTS AND METHODS: Patients with either low- or intermediate-grade DCIS measuring 2.5 cm or smaller, or high-grade DCIS measuring 1 cm or smaller who had microscopic margin widths of 3 mm or wider and no residual calcifications on postoperative mammograms were eligible for a prospective trial conducted from 1997 to 2002 by the Eastern Cooperative Oncology Group and North Central Cancer Treatment Group. Patients entered in 2000 and later could take tamoxifen if they wished. Median age at last surgery for the entire population was 60 years (range, 28 to 88 years), and median tumor sizes in the two strata were 6 mm and 5 mm, respectively.
RESULTS: With a median follow-up of 6.2 years, the 5-year rate of ipsilateral breast events in the 565 eligible patients in the low/intermediate grade stratum was 6.1% (95% CI, 4.1% to 8.2%). With a median follow-up of 6.7 years, this incidence for the 105 eligible patients in the high-grade stratum was 15.3% (95% CI, 8.2% to 22.5%).
CONCLUSION: Rigorously evaluated and selected patients with low- to intermediate-grade DCIS with margins 3 mm or wider had an acceptably low rate of ipsilateral breast events at 5 years after excision without irradiation. Patients with high-grade lesions had a much higher rate, suggesting that excision alone is inadequate treatment. Further follow-up is necessary to document long-term results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826126      PMCID: PMC2773217          DOI: 10.1200/JCO.2009.21.8560

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

1.  Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations.

Authors:  I de Mascarel; F Bonichon; G MacGrogan; C T de Lara; A Avril; V Picot; M Durand; L Mauriac; M Trojani; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  2000-05       Impact factor: 4.872

Review 2.  Side effects of adjuvant treatment of breast cancer.

Authors:  C L Shapiro; A Recht
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.

Authors:  L J Solin; J Kurtz; A Fourquet; R Amalric; A Recht; B A Bornstein; R Kuske; M Taylor; W Barrett; B Fowble; B Haffty; D J Schultz; I T Yeh; B McCormick; M McNeese
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

4.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  B Fisher; S Land; E Mamounas; J Dignam; E R Fisher; N Wolmark
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

5.  The influence of margin width on local control of ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; M D Lagios; S Groshen; J R Waisman; B S Lewinsky; S Martino; P Gamagami; W J Colburn
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

6.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Authors:  B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

7.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Authors:  Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

Review 8.  259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.

Authors:  Salomone Di Saverio; Fausto Catena; Donatella Santini; Luca Ansaloni; Tommaso Fogacci; Stefano Mignani; Antonio Leone; Filippo Gazzotti; Stefano Gagliardi; Angelo De Cataldis; Mario Taffurelli
Journal:  Breast Cancer Res Treat       Date:  2007-08-09       Impact factor: 4.872

9.  Trends in the treatment of ductal carcinoma in situ of the breast.

Authors:  Nancy N Baxter; Beth A Virnig; Sara B Durham; Todd M Tuttle
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

10.  Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.

Authors:  Lars Holmberg; Hans Garmo; Bengt Granstrand; Anita Ringberg; Lars-Gunnar Arnesson; Kerstin Sandelin; Per Karlsson; Harald Anderson; Stefan Emdin
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

View more
  74 in total

1.  [Radiotherapy also for good-risk ductal carcinoma in situ? Results from a prospective randomized RTOG trial].

Authors:  Rainer Souchon
Journal:  Strahlenther Onkol       Date:  2015-06       Impact factor: 3.621

2.  [Adjuvant radiotherapy significantly also reduces local recurrence rate for prognostically favorable DCIS].

Authors:  René Pahl; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2015-12       Impact factor: 3.621

3.  Ductal Carcinoma in Situ: Clinical Perspective.

Authors:  Thorsten Kühn
Journal:  Breast Care (Basel)       Date:  2010-08-02       Impact factor: 2.860

Review 4.  Oncoplastic breast surgery combining partial mastectomy with immediate breast reshaping using a keyhole-shaped skin glandular flap for Paget's disease.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Akihiro Nakajo; Hideo Arima; Hiroshi Okumura; Takaaki Arigami; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-08-08       Impact factor: 2.549

5.  Ductal carcinoma in situ: a rose by any other name.

Authors:  D Lawrence Wickerham; Thomas B Julian
Journal:  J Natl Cancer Inst       Date:  2013-09-25       Impact factor: 13.506

Review 6.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ.

Authors:  Shi-Yi Wang; Haitao Chu; Tatyana Shamliyan; Hawre Jalal; Karen M Kuntz; Robert L Kane; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2012-03-22       Impact factor: 13.506

Review 7.  Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:  Lawrence J Solin
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

8.  Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?

Authors:  Daniel X Choi; Anne A Eaton; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2012-11-19       Impact factor: 5.344

9.  Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.

Authors:  Christopher J Vandenbussche; Nagi Khouri; Eman Sbaity; Theodore N Tsangaris; Russell Vang; Armanda Tatsas; Ashley Cimino-Mathews; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

10.  Oncoplastic breast surgery combining periareolar mammoplasty with volume displacement using a crescent-shaped cutaneous flap for early breast cancer in the upper quadrant.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Akihiro Nakajo; Hideo Arima; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-02-27       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.